Angela Merkel in Bengaluru, PM Modi to join her

New Delhi, Jun 9: BJP leader Jyotiraditya Scindia and his mother Madhavi Raje Scindia have tested positive for COVID-19 and are currently undergoing treatment in a Delhi hospital, India Today reported on Tuesday.

They were admitted on Monday to Max Super Specialty Hospital, Saket, after the two complained of throat irritation and fever.

"Not so good news: @JM_Scindia and his mother have tested positive for corona, The former Cong turned BJP leader from MP has been admitted to hospital.. Wish him a speedy recovery!" tweeted Rajdeep Sardesai, consulting editor at the India Today group.

Breaking now: Not so good news: @JM_Scindia and his mother have tested positive for corona, The former Cong turned BJP leader from MP has been admitted to hospital.. Wish him a speedy recovery!  @IndiaToday

— Rajdeep Sardesai (@sardesairajdeep) June 9, 2020

Scindia, former Congress MP from Guna constituency in Madhya Pradesh, quit the party and joined BJP last March. Scindia, who was once Minister of State with independent charge for Power, is the BJP candidate for the upcoming Rajya Sabha elections from Madhya Pradesh.

New Delhi, Jul 11: Poll strategist Prashant Kishor took a swipe at Bihar Chief Minister Nitish Kumar on Saturday, saying this is time to fight the coronavirus not elections and that he should not endanger people's lives in a "hurry" to hold the assembly polls.

"The coronavirus situation in Bihar is worsening like it is in many other states of the country. But a big part of government machinery and resources are busy making preparation for the polls.

"Nitish Kumar ji, this isn't time to fight elections but the coronavirus. Don't endanger people's lives in this hurry to hold the polls," he tweeted.

Kishor, once a confidant of the JD(U) president before he turned a critic and was expelled from the party, joins leaders like LJP chief Chirag Paswan and RJD's Tejashwi Yadav in suggesting that the Bihar assembly polls should be deferred due to the pandemic.

Polls in Bihar are due in October-November but the Election Commission has so far not made any official announcement about its schedule.

The BJP and the JD(U) have been holding organisational meetings and said that they are ready for the elections.

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.